The product is care. The asset is the licence to deliver it. Photo: Marcelo Leal, Unsplash.
Nissha, the Kyoto technology group, took 60 percent of USM Healthcare in May, the Ho Chi Minh City factory that makes Vietnam's heart stents (Freshfields Vietnam M&A Spotlight, June 2026). Almost nobody covered it. The deal is the newest entry in a ledger that has been building for a decade: specialist money, most of it Singaporean, consolidating Vietnamese healthcare one asset class at a time. The buyers are quiet because they do not need attention. They need beds.
Executive summary
Control of Vietnamese healthcare is consolidating offshore. Thomson Medical paid about A$540 million for FV Hospital in 2023, the sector's record print (Thomson Medical announcement). Quadria Capital took the Tam Tri chain in 2025, Nissha took the stent maker and LeapFrog funded Pharmacity this year. Clermont has held Hoan My since 2013 and GIC holds a cornerstone in Vinmec.
The demand anchor is a single flow: roughly A$2.8 billion a year of Vietnamese spending on treatment abroad, against a public system reporting occupancy above 100 percent and out-of-pocket payments near 40 percent of the national health bill.
Three theses explain the timing: defensive, self-paid cash flows in a cyclical market, a scarcity premium on licensed capacity that makes M&A the only fast entry, and an open exit window as first-generation founders and funds reach their sales.
The structural edge: hospitals are among the few Vietnamese assets open to 100 percent foreign ownership, so control is actually buyable.
The risks are supply-side: clinicians, licence transfers, and a state that can regulate any margin it starts to notice.
Two calls to mark: another hospital-chain control sale by 30 June 2027, and a second Japanese acquisition of a Vietnamese medical manufacturer within twelve months.
1. Market analysis
The revenue pool is large, growing and self-funded. Vietnam has 100 million people, health spending that grows faster than nominal GDP in every serious forecast, and out-of-pocket payments carrying roughly 40 percent of the bill (WHO country data). Fitch Solutions' standing forecast puts the pool near A$33 billion this year and A$48 billion by 2030, growth of about 8 percent a year. In plain terms: patients pay cash, which strips reimbursement risk out of the revenue line and makes a hospital's earnings unusually easy to underwrite.
Supply is the constraint. Central public hospitals have reported occupancy above 100 percent (health ministry figures via state media), private facilities hold a single-digit share of national bed capacity, and the top of the market leaks offshore: about A$2.8 billion a year flies to Singapore and Bangkok for treatment, on figures the health ministry has cited for years. That flow is revealed demand for premium care, priced annually, and it is the number every acquirer puts at the top of the model. Thomson did not buy a building. It bought the front of the queue to Singapore.
The regulatory setup finishes the case. Hospitals have been open to full foreign ownership since Vietnam joined the WTO, a rarity in a market that caps banks at 30 percent, and healthcare has been running alongside industrials and technology at about 38 percent of monthly deal count (Freshfields, May 2026). Deal flow is no longer episodic. It is a pipeline.
2. The ledger
The record is a single hospital. Thomson Medical, the Singapore-listed operator, paid about A$540 million in 2023 for FV Hospital in Ho Chi Minh City, still the sector's largest transaction (company announcement). In July 2025, Quadria Capital's Singapore vehicle took 73.15 percent of the Tam Tri hospital chain, buying VinaCapital's listed fund out of its 37.8 percent stake (The Investor). GIC put about A$290 million into Vinmec, Vingroup's hospital arm, in December 2020 (Vingroup announcement), and backs the 315 clinic chain besides. Hoan My, the country's largest private hospital group, has answered to Singapore's Clermont Group since 2013.
This year the front widened. Nissha took the stent maker. LeapFrog Investments led a round of up to roughly A$110 million in Pharmacity, the drugstore chain (Freshfields). Dawn Medical took control of Pinnacle Health. Every seat at the table is filled, and none of the name cards is Australian.
3. The buyer taxonomy
Three classes of capital are bidding, and each is underwriting something different. Strategics pay for control and synergy. The FV print bought Thomson a platform it can operate outright, and the USM stake bought Nissha manufacturing capacity as Japanese home demand shrinks. A control premium makes sense when the asset plugs into an existing operating business.
Financial sponsors underwrite growth at an exit multiple inside a hold period. The Tam Tri deal bought Quadria a hospital platform with a credible path to a bigger number at exit, and LeapFrog's Pharmacity round, covered below, is the same trade in retail. Permanent capital pays for duration. GIC's Vinmec cornerstone and Clermont's second decade holding Hoan My need no exit date at all. Operators buy machines, funds buy trajectories, and permanent capital buys time.
Ho Chi Minh City, home of the A$540 million record print. Photo: Peter Nguyen, Unsplash.
4. Three theses for why the buyers move now
Thesis one: defensive growth is scarce, and healthcare has it. Vietnamese property carries land-fee risk, banking carries a 30 percent foreign cap, and exporters carry tariff beta. Hospital revenue is none of those things. It is non-cyclical, self-paid and compounding with demographics, which is why strategic buyers underwrite it at premiums financial buyers struggle to match. The buyers are not paying for growth. They are paying for certainty of growth.
Thesis two: licensed capacity trades at a scarcity premium. A foreign-standard hospital in Vietnam takes years to license, staff and accredit, and the clinician market is thin. Replacement cost is therefore not the build cost, it is the decade of lead time, and a control transaction collapses that decade into a completion date. The FV print made the arithmetic public. Every operator running the same model reaches the same answer: buying is cheaper than building once time is priced.
Thesis three: the exit window is open, and windows close. Funds are at the end of hold periods, which is why VinaCapital sold into the Tam Tri transaction. Founders who built chains in the 1990s and 2000s are reaching succession without successors. And the buyer set runs on its own clock: Japanese strategics face shrinking home markets and hold cheap balance-sheet funding, while Singapore's operators need bolt-on growth to defend their own multiples. Each completed print marks the next asset up. Waiting is not free.
5. Segment economics
Hospitals are scarcity assets. Out-of-pocket payments near 40 percent of national health spending mean private beds earn self-paid revenue that clears once occupancy fills, and it fills fast against a public system running past its rated capacity. The acquirer is buying a licence and a clinician roster that take years to assemble, so replacement cost is measured in lead time, not concrete. The FV print took the trophy-single route. The Tam Tri deal took the roll-up route. Both prices buy the same thing: permission to operate.
Devices are a cost-base trade with a strategic kicker. The USM stake hands Nissha a licensed, accredited production line in a market where licensing takes years to win, priced off a Vietnamese cost base, with an export book attached. The buyer is not paying for current revenue. It is paying for the years the licence already cost somebody else.
Pharmacy retail is a land grab. LeapFrog led its round into Pharmacity even though FPT's Long Chau is winning the store-count race, because store networks reward density, a two-chain race on store count is what formalisation looks like, and the number two in a formalising market is cheap enough to underwrite. In plain terms: hospitals sell permission, factories sell cost, and pharmacies sell the shelf closest to the customer.
6. Risk factors
Six things could break the thesis.
The scarce input is not the equipment. It is the specialist holding it. Photo: Hush Naidoo Jade Photography, Unsplash.
Clinician supply. Vietnam's specialist market is thin, so any roll-up that adds beds faster than it hires surgeons ends up owning capacity it cannot staff. Roll-up speed is capped accordingly.
Pricing intervention. A state that watches A$2.8 billion a year leave for treatment abroad can just as easily decide private hospital margins are a policy problem and regulate them.
Public catch-up. The same over-100-percent occupancy that makes private beds scarce also invites a public investment response, and every new state bed erodes the private premium.
Key-person dependence. If these chains follow the founder-built pattern common to first-generation private hospitals, a control sale tests whether patients follow the brand or the departing doctor.
Valuation risk. The FV print marked the sector up in one transaction, so later buyers underwrite multiples set by a single competitive auction rather than by earnings.
Integration friction. Licences and accreditation take years under Vietnamese rules, and a control deal must transfer permits and retain clinicians before any synergy reaches the numbers. The patients exist. Doctors, licences and a watchful state decide how fast anyone gets paid.
7. Pipeline and watchlist
None of this is reported. It is inference from the deal pattern above. Start with Clermont, owner of Hoan My since 2013. Permanent capital carries no fund clock, but Clermont is entering a second decade of ownership and the FV print marked the sector up beneath it. That is when profits usually get taken.
Sponsors run in the opposite direction. On a typical four-to-six-year hold, Quadria's and LeapFrog's exits land 2029 to 2031, so their bolt-on acquisitions land now, and founder-owned single hospitals and provincial chains are the obvious feedstock. Devices are scarcer still. The USM stake takes a licensed Vietnamese manufacturer off the shelf in a market where licences take years to win, and Japan's 705,809 births last year, a tenth consecutive record low (Japan's health ministry), argue the next bidder is Japanese too. Watch long-term owners selling, new owners buying small, and Japanese buyers shopping for factories.
8. The Australian position
Australia used to hold this exact hand. Ramsay Health Care, the largest hospital operator the country has produced, ran an Asian joint venture for a decade and sold out of it in 2023. The proceeds went home. No ASX-listed operator, insurer or fund has taken a Vietnamese healthcare position since. That is one sentence of an old story, so here are two new ones instead.
Call one: another Vietnamese private hospital chain announces a control sale by 30 June 2027. The sellers are queued the way the patients are. Call two: within twelve months, a second Japanese strategic buys a Vietnamese medical manufacturer, running Nissha's play of buying production where the patients are and the workers still exist. Mark both.
Healthcare is the quietest big trade in Vietnam because its buyers do not hold press conferences. The sellers are Vietnamese founders and exiting funds. The owners, increasingly, are two flight hours away.
The stent maker is Japanese, the hospitals bank to Singapore, and A$2.8 billion of patients still fly out every year. The buyers are not early. They are on time.
General commentary only. Not financial product advice.